Skip to main content

Table 2 Transition matrix for the treatment pathway metformin+dipeptidyl peptidase-4 inhibitor

From: Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes

  

To t + 1

  

Metformin monotherapy

Metformin +DPP-4i

Metformin +DPP-4i + Basal insulin

Death

From t

Metformin monotherapy

#

0.046

0

60–70 years; 0.021

71–80 years; 0.051

81–85 years; 0.107

 

Metformin +DPP-4i

0

#

0.013

60–70 years; 0.021

71–80 years; 0.051

81–85 years; 0.107

 

Metformin +DPP-4i + Basal insulin

0

0

#

60–70 years; 0.021

71–80 years; 0.051

81–85 years; 0.107

 

Death

0

0

0

1

  1. Acronyms: DPP-4i-dipeptidyl peptidase-4 inhibitors